Sign In
Buy RDHL
$1.00
-0.0100 (-0.99%)
At Close: Jun 03, 2026
New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality
07:00am, Tuesday, 03'rd Sep 2024
Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement in
RedHill Biopharma Announces First Half 2024 Business Highlights
07:00am, Thursday, 29'th Aug 2024
A transformed RedHill: Numerous potential catalysts Strengthened cash balance and control over our destiny following the Termination Agreement with Movantik Acquisition Co. and others : Executing o
RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma
07:00am, Monday, 26'th Aug 2024
Neuroblastoma is rare but is the most common infancy malignancy with a median age of diagnosis of 17 months. In the U.S., it accounts for up to around 10% of all childhood cancer cases and 15% of pedi
Talicia® Launched in the United Arab Emirates
07:00am, Wednesday, 21'st Aug 2024
RedHill's Talicia, the first approved low-dose rifabutin-containing all-in-one combination treatment for H. pylori, is now available on prescription to treat adults with H.
Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes
08:56am, Monday, 19'th Aug 2024
On Monday, RedHill Biopharma Ltd. RDHL released results from multiple in vivo studies, undertaken by RedHill's partner, Apogee Biotechnology Corporation.
RedHill Announces Positive Obesity and Diabetes Results with Opaganib
07:00am, Monday, 19'th Aug 2024
The global obesity-diabetes drugs market is projected to be worth around $100 billion by 2034 [1] – largely driven by Glucagon-like peptide-1 (GLP-1) inhibitors like Novo Nordisk's Ozempic® and W
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
07:00am, Friday, 16'th Aug 2024
TEL AVIV, Israel and RALEIGH, N.C. , Aug. 16, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.
Why Is RedHill Biopharma (RDHL) Stock Up 75% Today?
02:11pm, Thursday, 01'st Aug 2024
One of today's biggest movers in the biotech sector is RedHill Biopharma (NASDAQ: RDHL ), a little-known specialty player in the space focusing on gastrointestinal and infectious diseases. Today, RDHL
Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease
07:00am, Thursday, 01'st Aug 2024
Newly published in the peer-reviewed journal Antibiotics, the 331-patient Phase 3 Crohn's disease study data shows the primary endpoint of clinical remission at week 26 was achieved, with high statist
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien
07:00am, Monday, 22'nd Jul 2024
TEL-AVIV, Israel and RALEIGH, NC , July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing
RedHill Biopharma Terminates License Agreement for Aemcolo®
08:00am, Tuesday, 09'th Jul 2024
TEL-AVIV, Israel and RALEIGH, NC , July 9, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the mutual d
RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
07:00am, Monday, 03'rd Jun 2024
New Chinese patent notice of allowance issued covering opaganib in combination with immune checkpoint inhibitors (ICIs) as a method of inducing an anti-cancer immune response [1] . Provides protection
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
07:00am, Monday, 06'th May 2024
The new Chinese patent for opaganib as a therapy for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) is valid through 2035 and adds to opaganib's strong global intell
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
07:00am, Wednesday, 24'th Apr 2024
First patient enrolled in the global, 300-patient, Phase 2 adaptive platform trial arm of RHB-107 (upamostat)1 for early COVID-19 outpatient treatment, funded through non-dilutive external sources,
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
09:23am, Monday, 08'th Apr 2024
RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base Focused externally funded
